<DOC>
	<DOCNO>NCT00203671</DOCNO>
	<brief_summary>The purpose study : - To review past clinical use mycophenolate mofetil ( MMF ) kidney transplant patient ; - To discover dos modify modification affect survival health transplant kidney ; - To determine whether , therefore , side effect MMF result dose alteration related outcome .</brief_summary>
	<brief_title>Mycophenolate Mofetil ( MMF ) : A Long-Term Data Evaluation</brief_title>
	<detailed_description>Objectives : We propose collect data MMF total daily dose regimen use transplant population 1995 2003 . We assess dos modify modification affect graft survival , whether , therefore , side effect MMF result dose alteration related outcome . Implementation 1 . Phase I - To describe initial MMF dose subsequent change 2 . Phase II - To explore potential effect graft outcomes 3 . Phase III - To explore reason dose change relate tolerability PHASE I 1 . The initial maintenance total daily dose mycophenolate mofetil ( MMF , Cellcept ) ( Frequency distribution initial maintenance total daily dose mg/day ) Include subgroup information : 1 . Cadaveric donor vs. living donor 2 . Regimen ( BID vs. TID vs. QID ) 3 . Race ( AA vs. Others ) 2 . Changes MMF dose Initial Maintenance Dose ( censor patient info time rejection graft loss ) 1 . To answer question look time point capture within first post-transplant year , 1 , 3 , 6 , 9 12 month post-transplant , whichever few . 2 . We analyze frequency distribution daily dos subgroup cadaveric donor vs. live donor sub-group . 3 . Patients change MMF total daily dose first year post-transplant . No dose change define MMF dose time period . 4 . Patients MMF permanently discontinue first year post-transplant . 5 . Patients dose reduction first post-transplant year . 6 . Patients frequency MMF daily regimen increase ( i.e. , BID TID QID ) first post-transplant year . PHASE II 1 . Acute Rejection 1 . Using data Statement 2A assess many patient experience treated acute rejection , stratify dose `` total-daily-dose group '' warrant frequency distribution . 2 . Using data Statement 2 B , C , &amp; D , analyze whether MMF discontinuation , dose reduction , increase MMF dose frequency associate incidence ( subsequent ) acute rejection ? 2 . Graft failure 1 . Using data Statement 2A , document many patient graft failure . 2 . Using data Statement 2 B , C , &amp; D , analyze whether MMF discontinuation , MMF dose reduction , increase MMF dose frequency affect incidence graft failure ? PHASE III 1 . Reasons Dose Reduction The side effect result dose reduction document effect dose reduction subsequent period analyze .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Renal transplant recipient either cadaveric living donor kidney . 18 year age old . Multiple organ transplant recipient . Prior kidney transplant recipient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>renal</keyword>
	<keyword>transplant</keyword>
	<keyword>kidney</keyword>
	<keyword>rejection</keyword>
	<keyword>MMF</keyword>
	<keyword>Mycophenolate Mofetil</keyword>
	<keyword>outcome</keyword>
	<keyword>Kidney Transplantation</keyword>
</DOC>